Can cannabis ease endometriosis pain? What does the evidence show?

Pain can dominate daily life

Endometriosis-associated pain may occur during periods, between periods, during intercourse, urination or bowel movements. It can radiate into the back or legs and substantially affect sleep and function. Pain mechanisms vary among patients.

Three plausible biological targets

Cannabinoid research examines peripheral pain nerves, immune-mediated inflammation around lesions and central processing of pain. CB1 is involved in neuronal signaling; CB2 and other molecular targets may participate in immune pathways. Plausibility is different from proven treatment efficacy.

Observational data versus controlled trials

Self-report surveys and observational cohorts include reports of reduced pain or improved sleep among people who use cannabis. Yet the studies often lack random assignment, blinded controls and standardized products. Placebo effects, selection bias and other therapies can influence outcomes.

A feasibility randomized trial published in 2025 enrolled 12 participants, but only four completed the study. Recruitment and retention difficulties meant it could not establish treatment effectiveness. This trial illustrates why larger, well-conducted studies are still needed. 2025 feasibility trial ↗

THC, CBD, dose and delivery

Products differ greatly in THC and CBD concentrations, delivery route and duration of action. No specific product or dose is supported by sufficiently reliable evidence for endometriosis pain. THC can cause intoxication, anxiety, impairment or dependence; CBD also has possible adverse effects and drug interactions.

Pain relief is not lesion regression

Even a meaningful reduction in pain would not prove that lesions have shrunk, inflammation has resolved or fertility has improved. Symptom management and disease monitoring are separate goals, as in other chronic inflammatory conditions.

What high-quality research must answer

Better randomized trials should measure pain, quality of life, reasons for stopping treatment, adverse effects and outcomes over time, while distinguishing formulations. Reproductive safety and fertility outcomes are especially important.

Key conclusion

Some patients report relief, and there are mechanistic reasons to investigate cannabinoids. Controlled clinical evidence remains too limited to claim that cannabis reliably treats endometriosis or prevents progression. Decisions belong within individualized medical care.

Source article and references

This article is an editorial adaptation of the Hebrew original.

Read the Hebrew source article ↗